Clinical Trials Browser

Phase 2 × OTHER × encorafenib × Clear all

NCT04074096 2026-06-05

BEPCOME-MB

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05576896 2026-06-04

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05026983 2026-04-16

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Phase 2 Recruiting

Melanoma

NCT04061980 2026-04-13

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Phase 2 Active not recruiting

Thyroid Neoplasms

NCT06578559 2026-01-05

BRICKET

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04526782 2025-11-18

ENCO-BRAF

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05510895 2025-10-01

NeoBRAF

Phase 2 Completed

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT06887088 2025-10-01

ENCEFALO

Phase 2 Recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT07178717 2025-09-17

REFISH

Phase 2 Not yet recruiting

Gastrointestinal

Colonic Neoplasms

NCT05706779 2025-09-02

NEORAF

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03898908 2025-05-21

EBRAIN-MEL

Phase 2 Completed

48 enrolled 24 charts

CNSDermatologic

Brain Neoplasms, Melanoma, Neoplasm Metastasis

NCT06640166 2025-02-12

ECLYPse

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT03839342 2025-02-03

BEAVER

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT06411600 2024-11-08

BRAVE

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03973918 2024-10-31

BRAF

Phase 2 Terminated

5 enrolled 15 charts

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

NCT01894672 2024-07-16

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Phase 2 Completed

7 enrolled 9 charts

Melanoma

NCT02631447 2024-06-07

SECOMBIT

Phase 2 Completed

Melanoma

NCT04390243 2024-05-06

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Phase 2 Terminated

6 enrolled 16 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02834364 2023-11-24

GMMG-BIRMA

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT03563729 2023-07-13

MEMBRAINS

Phase 2 Recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05767879 2023-03-14

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Phase 2 Unknown

Melanoma

NCT05725200 2023-02-21

EVIDENT

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05097378 2021-10-28

PREMIUM

Phase 2 Unknown

Melanoma, Neoplasms

NCT02263898 2020-07-27

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Phase 2 Withdrawn

Melanoma